387 results match your criteria Gastrointestinal Cancer Research GCR [Journal]


A case of primary colonic small-cell carcinoma arising in a patient with long-standing ulcerative colitis.

Gastrointest Cancer Res 2014 May;7(3-4):119-22

Neag Comprehensive Cancer Center University of Connecticut Health Center Farmington, CT.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171971PMC
May 2014
8 Reads

Metastatic breast cancer masquerading as primary gastric cancer: case report and review of the literature.

Gastrointest Cancer Res 2014 May;7(3-4):117-8

Department of Pathology Huntington Medical Center Pasadena, CA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171973PMC
May 2014
6 Reads

Pseudomyxoma peritonei metastatic to the bone: case report and review of systemic management.

Gastrointest Cancer Res 2014 May;7(3-4):108-10

Department of Medical Oncology BC Cancer Agency Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171977PMC
May 2014
7 Reads

From the liver to the foot: a case of systemic embolism and acrometastasis in hepatocellular carcinoma.

Gastrointest Cancer Res 2014 May;7(3-4):103-7

Memorial Sloan-Kettering Cancer Center New York, NY ; Weill Cornell Medical College New York, NY.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171976PMC
May 2014
10 Reads

Challenges in combining antiangiogenic therapy with transarterial chemoembolization for hepatocellular carcinoma.

Gastrointest Cancer Res 2014 May;7(3-4):98-102

Divison of Oncology.

Background: The combination of systemic antiangiogenic therapy and transarterial chemoembolization (TACE) for the treatment of unresectable hepatocellular carcinoma (HCC) is the subject of several ongoing clinical trials. We present a series of patients treated with sorafenib and TACE at our institution, highlighting the technical challenges of combining these two modalities of treatment.

Methods: We retrospectively identified patients with HCC treated with TACE and sorafenib at our institution. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171975PMC
May 2014
15 Reads

Maintenance therapy with capecitabine in patients with resected pancreatic adenocarcinoma after adjuvant therapy: a retrospective cohort study.

Gastrointest Cancer Res 2014 May;7(3-4):91-7

Levine Cancer Institute Carolinas Medical Center Charlotte, NC.

Background: The 5-year survival of pancreatic adenocarcinoma with surgery and adjuvant chemotherapy is below 25%. The original Gastrointestinal Tumor Study Group (GITSG) adjuvant study demonstrated a survival benefit attributed to weekly intravenous boluses of 5-fluorouracil (5-FU) for 2 years in addition to chemoradiation compared to surgery alone. In theory, the prolonged exposure to therapy could maintain pressure on dormant cancer cells that remain in G0 arrest and kill them as they infrequently enter the G1/S phase. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171974PMC
May 2014
12 Reads

Benefit of Adjuvant Chemoradiotherapy for Gastric Adenocarcinoma: A SEER Population Analysis.

Gastrointest Cancer Res 2014 May;7(3-4):82-90

Department of Radiation Oncology David Geffen School of Medicine at UCLA Los Angeles, CA.

Background: Despite results of the Intergroup 0116 (INT-0116) study showing an overall survival benefit of adjuvant chemoradiotherapy in gastric adenocarcinoma, its use in the United States remains controversial. The Surveillance Epidemiology of End Results (SEER) database was used to compare cause-specific survival outcomes in resected gastric adenocarcinoma with various adjuvant therapies and patterns of care.

Methods: Individual data from 1988 to 2008 were selected for patients with resected, nonmetastatic gastric adenocarcinoma. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171970PMC
May 2014
4 Reads

Quantitative perfusion- and diffusion-weighted magnetic resonance imaging of gastrointestinal cancers treated with multikinase inhibitors: a pilot study.

Gastrointest Cancer Res 2014 May;7(3-4):75-81

Department of Medicine.

Background: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging (DWI) are often used to detect the early response of solid tumors to an effective therapy. The early changes in intratumoral physiological parameters measured by DCE-MRI/DWI have been evaluated as surrogate biomarkers allowing a tailored treatment for the individual patient.

Methods: Patients with newly diagnosed, biopsy-proven, treatment-naïve gastrointestinal stromal tumor (GIST) or hepatocellular carcinoma (HCC) were enrolled prospectively after institutional review board (IRB)-approved informed consent (5 patients per tumor type). Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171969PMC
May 2014
13 Reads

Clinical Applications of Liquid Biopsies in Gastrointestinal Oncology.

Gastrointest Cancer Res 2014 Sep;7(4 Suppl 1):S8-S12

Department of Gastrointestinal Medical Oncology University of Texas MD Anderson Cancer Center Houston, TX.

Accumulating knowledge in colorectal cancer (CRC) biology has led to an understanding of the role of genetic and epigenetic alterations in tumorigenesis and progression of the disease. Numerous studies have focused on the identification of novel biomarkers in circulating free (cf)DNA that have the potential of guiding clinical practice. These markers are specifically attractive for the characterization of molecular profiles in patients with limited tissue access, the monitoring of therapeutic responses and the development of recurrent disease, the monitoring of the tumor evolution with therapy, and the response to therapy. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4812842PMC
September 2014
3 Reads

Novel Therapies in Development for Metastatic Colorectal Cancer.

Gastrointest Cancer Res 2014 Sep;7(4 Suppl 1):S2-7

Department of Gastrointestinal Medical Oncology University of Texas MD Anderson Cancer Center Houston, TX.

Colorectal cancer (CRC) is the second most common cause of cancer mortality in the United States. Despite advances in therapy, metastatic CRC remains lethal, and further improvements in therapy are needed. Growing understanding of cancer biology, particularly in growth factor signaling, angiogenesis, and cancer immunology, has translated into many novel therapies under investigation. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4812839PMC
September 2014
3 Reads

Upcoming articles.

Authors:

Gastrointest Cancer Res 2014 Mar;7(2):74

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007684PMC
March 2014
4 Reads

Definitive chemoradiation in oligometastatic squamous cell carcinoma of the anal canal.

Gastrointest Cancer Res 2014 Mar;7(2):65-8

Department of Gastrointestinal Medical Oncology University of Texas M.D. Anderson Cancer Center Houston, TX.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007681PMC
March 2014
45 Reads

Metastatic non-small-cell lung cancer to the liver and pancreas.

Gastrointest Cancer Res 2014 Mar;7(2):61-2

Edwards Comprehensive Cancer Center Cabell Huntington Hospital Huntington, West Virginia ; Joan C. Edwards School of Medicine Marshall University Huntington, West Virginia.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007679PMC
March 2014
4 Reads

Acute gout episodes during treatment with capecitabine: a case report.

Gastrointest Cancer Res 2014 Mar;7(2):59-60

Department of Medical Oncology BC Cancer Agency Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007678PMC
March 2014
4 Reads

A 39-year-old female patient with metastatic rectal cancer develops thrombocytopenia.

Gastrointest Cancer Res 2014 Mar;7(2):55-8

Memorial Sloan-Kettering Cancer Center New York, NY ; Weill Cornell Medical College New York, NY.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007677PMC
March 2014
7 Reads

Prognosis of Patients With Fibrolamellar Hepatocellular Carcinoma Versus Conventional Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.

Gastrointest Cancer Res 2014 Mar;7(2):49-54

Division of Gastroenterology and Hepatology Mayo Clinic Rochester, MN.

Background: Emerging data suggest that the fibrolamellar variant of hepatocellular carcinoma (FL-HCC) differs in clinical course and prognosis from conventional (nonfibrolamellar) HCC (NFL-HCC). Although FL-HCC is believed to have a better prognosis than NFL-HCC, data comparing the prognoses of the two types of HCC remain lacking. The aim of this systematic review was to compare the prognosis of FL- vs. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007676PMC
March 2014
5 Reads

Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer.

Gastrointest Cancer Res 2014 Mar;7(2):42-8

Gastrointestinal Medical Oncology UT-MD Anderson Cancer Center Houston, TX.

Background: The HER2/neu gene is a proto-oncogene that can predict the response to treatment with trastuzumab, pertuzumab, and lapatinib. This study was conducted to determine the frequency of HER2/neu overexpression and to identify a subgroup of patients with gallbladder cancer who would benefit from targeted therapy.

Methods: Patients with gallbladder cancer (n = 187; 165 women and 22 men) with a recorded follow-up of at least 5 years were included, along with control subjects (n = 75). Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007675PMC
March 2014
10 Reads

Absence of anaplastic lymphoma kinase translocations in signet ring cell carcinomas of the upper gastrointestinal tract.

Gastrointest Cancer Res 2014 Mar;7(2):39-41

Division of Hematology Oncology The University of Vermont Cancer Center Burlington, VT.

Background: Anaplastic lymphoma kinase (ALK) fusion oncogenes are present in multiple cancer types. The inversion of echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) genes on chromosome 2 is present in a subset of patients with non-small-cell lung cancer (NSCLC). ALK-rearranged lung cancers demonstrate a significantly higher incidence of signet ring cell histology than do ALK-negative tumors. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007674PMC
March 2014
5 Reads

Upcoming articles.

Authors:

Gastrointest Cancer Res 2014 Jan;7(1):38

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924765PMC
January 2014
3 Reads

Tumor rupture as the initial manifestation of primary hepatic leiomyosarcoma.

Gastrointest Cancer Res 2014 Jan;7(1):33-4

Division of Gastroenterology Hartford Hospital Hartford, CT.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924763PMC
January 2014
4 Reads

A woman with metastatic pancreatic neuroendocrine tumor.

Gastrointest Cancer Res 2014 Jan;7(1):27-32

Memorial Sloan-Kettering Cancer Center New York, NY ; Weill Medical College at Cornell University New York, NY.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924762PMC
January 2014
26 Reads

KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model.

Gastrointest Cancer Res 2014 Jan;7(1):23-6

Haematology-Oncology Department Basil Hetzel Institute for Translational Health Research The Queen Elizabeth Hospital Woodville, South Australia, Australia ; Department of Physiology School of Medical Sciences University of Adelaide Adelaide, South Australia, Australia.

Background: The treatment of metastatic colorectal cancer (mCRC) includes drugs targeting the epidermal growth factor receptor (EGFR). Mutation in codon 12 or 13 in the Kirsten rat sarcoma viral oncogene homolog (KRAS) gene, downstream of the EGFR, evokes constitutive activation of the RAS/RAF/MAPK signaling pathway and correlates with resistance to anti-EGFR monoclonal antibody (mAb) therapies. However, a retrospective study reported that a proportion of patients with the KRAS G13D mutation may respond to cetuximab. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930148PMC
January 2014
47 Reads
17 Citations

Accelerated fraction radiotherapy with capecitabine as neoadjuvant therapy for borderline resectable pancreatic cancer.

Gastrointest Cancer Res 2014 Jan;7(1):15-22

Cancer Center ; Department of Medicine Division of Hematology/Oncology ; Department of Medicine Division of Hematology/Oncology University of North Carolina Chapel Hill, NC.

Background: A standard neoadjuvant regimen has not been defined for borderline resectable (BR) pancreatic cancer. This phase II trial was designed to determine the safety of accelerated fraction radiotherapy (AFRT) with capecitabine in patients with BR pancreatic cancer.

Methods: The patients had newly diagnosed BR adenocarcinoma of the pancreas and normal organ function. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924761PMC
January 2014
13 Reads

ACR Appropriateness Criteria®-Anal Cancer.

Gastrointest Cancer Res 2014 Jan;7(1):4-14

Cancer Center of Santa Barbara, Santa Barbara, CA.

The management of anal cancer is driven by randomized and nonrandomized clinical trials. However, trials may present conflicting conclusions. Furthermore, different clinical situations may not be addressed in certain trials because of eligibility inclusion criteria. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924766PMC
January 2014
25 Reads

Intrahepatic cholangiocarcinoma: are we doing the right thing?

Authors:
Basile Njei

Gastrointest Cancer Res 2014 Jan;7(1):1-3

Department of Medicine University of Connecticut Farmington, CT.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924760PMC
January 2014
5 Reads

Upcoming articles.

Authors:

Gastrointest Cancer Res 2013 Sep;6(5-6):159

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849898PMC
September 2013
4 Reads

Metastatic colon cancer presenting as pituitary mass.

Gastrointest Cancer Res 2013 Sep;6(5-6):152-5

Department of Internal Medicine, Fairview Hospital.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849902PMC
September 2013
11 Reads

Melanoma metastasis to the gastric mucosa preceded by guillain-barré as a paraneoplastic syndrome.

Gastrointest Cancer Res 2013 Sep;6(5-6):150-1

Department of Internal Medicine and Medical Oncology Hospital Santo Antonio Blumenau, Santa Catarina, Brazil.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849897PMC
September 2013
5 Reads

Acute gastrointestinal toxicity and tumor response with preoperative intensity modulated radiation therapy for rectal cancer.

Gastrointest Cancer Res 2013 Sep;6(5-6):137-43

Department of Radiation Oncology ; Harvard Radiation Oncology Program Harvard Medical School Boston, MA.

Background: Preoperative chemoradiotherapy (preopCRT) for locally advanced rectal cancer is associated with grade 3 or higher acute gastrointestinal (GI) toxicity. This study was conducted to determine whether intensity-modulated radiation therapy (IMRT) significantly reduces acute GI toxicity, compared to 3-dimensional conformal RT (3D-CRT) in preopCRT for rectal cancer.

Methods: A retrospective analysis was conducted of 48 patients treated between January 2002 and August 2010 with preopCRT for rectal cancer. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849901PMC
September 2013
41 Reads

Predictors of acute gastrointestinal toxicity during pelvic chemoradiotherapy in patients with rectal cancer.

Gastrointest Cancer Res 2013 Sep;6(5-6):129-36

Department of Radiation Oncology.

Background: This study was conducted to identify the factors associated with acute gastrointestinal (GI) toxicity during pelvic chemoradiotherapy (PCRT) in patients with rectal cancer.

Methods: We analyzed 177 patients with rectal cancer treated from 2007 through 2010. Clinical information, including weekly diarrhea and proctitis toxicity grade during PCRT, was recorded. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849899PMC
September 2013
7 Reads

A Phase II Trial of Cetuximab, Gemcitabine, 5-Fluorouracil, and Radiation Therapy in Locally Advanced Nonmetastatic Pancreatic Adenocarcinoma.

Gastrointest Cancer Res 2013 Jul;6(4 Suppl 1):S2-9

Albert Einstein College of Medicine New York, NY.

Background: Pancreatic cancer is the fourth leading cause of cancer deaths in the United States. A minority of patients present with localized disease and surgical resection still offers patients the only hope for long-term survival. Locally advanced pancreatic cancer is defined as surgically unresectable, but has no evidence of distant metastases. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849911PMC
July 2013
17 Reads

Advances in the Treatment of Pancreatic Neuroendocrine Tumors (pNETs).

Gastrointest Cancer Res 2013 Jul;6(4 Suppl 1):S10-2

H. Lee Moffitt Cancer Center and Research Institute Department of GI Oncology Tampa, FL.

Recent clinical trials have led to significant advancements in treatment options for metastatic neuroendocrine tumors of the pancreas. Sunitinib and everolimus have been approved by the Food and Drug Administration for treatment of progressive pancreatic NETs based on phase III trial data demonstrating improvements in progression-free survival. Cytotoxic drugs such as temozolomide and capecitabine have been associated with high radiographic response rates; however data derives primarily from subset analysis of prospective trials and from retrospective series. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849907PMC
July 2013
3 Reads

Upcoming articles.

Authors:

Gastrointest Cancer Res 2013 Jul;6(4):128

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782875PMC
July 2013
4 Reads

A Case Report of an Extraintestinal GIST Presenting as a Giant Abdominopelvic Tumor.

Gastrointest Cancer Res 2013 Jul;6(4):120-2

Department of General Surgery.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782876PMC
July 2013
4 Reads

A Possible Role for TNF-α in Coordinating Inflammation and Angiogenesis in Chronic Liver Disease and Hepatocellular Carcinoma.

Gastrointest Cancer Res 2013 Jul;6(4):107-14

Department of Pathology.

Background: Increasing evidence supports the hypothesis that chronic and persistent inflammation contributes to cancer development. However, the molecular mechanisms that lead to cancer in chronic inflammation and the role of angiogenesis in inflammation-associated cancer remain poorly understood.

Methods: NINETY PATIENTS WERE ENROLLED: 30 cases of CHC without cirrhosis, 28 cases of CHC with liver cirrhosis, and 32 cases of HCC and hepatitis C virus infection. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782877PMC
July 2013
7 Reads
8 Citations

Bile duct involvement portends poor prognosis in resected gallbladder carcinoma.

Gastrointest Cancer Res 2013 Jul;6(4):101-5

Division of Surgical Oncology Oregon Health and Sciences University Portland, OR.

Background: Gallbladder cancer (GBC) carries an unfavorable prognosis with high mortality. This retrospective study was conducted to identify prognostic factors after resection of GBC, to assist in selecting appropriate surgical and adjuvant therapy.

Methods: Sixty-two patients from two institutions were identified with GBC by pathology. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782874PMC
July 2013
12 Reads

Upcoming articles.

Authors:

Gastrointest Cancer Res 2013 May;6(3):100

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3737507PMC
May 2013
4 Reads

An extremely rare case of pancreatic cancer presenting with leptomeningeal carcinomatosis and synchronous intraparenchymal brain metastasis.

Gastrointest Cancer Res 2013 May;6(3):90-2

Department of Internal Medicine West Penn Allegheny Health System Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3737512PMC
May 2013
17 Reads

Above-Label Doses of Octreotide-LAR in Patients With Metastatic Small Intestinal Carcinoid Tumors.

Gastrointest Cancer Res 2013 May;6(3):81-5

Department of GI Oncology Moffitt Cancer Center and Research Institute Tampa, FL.

Background: Octreotide LAR is indicated for treatment of malignant carcinoid syndrome and has been studied at doses of 10 to 30 mg intramuscularly every 4 weeks. In clinical practice, higher doses are often prescribed for patients who experience refractory carcinoid syndrome (flushing and/or diarrhea) or tumor growth while on the maximum label-recommended dose.

Methods: We performed a retrospective, longitudinal review of octreotide LAR administration at a tertiary institution to determine the frequency of above-label dosing and outcomes. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3737510PMC
May 2013
14 Reads

Characteristics and outcomes of adenosquamous carcinoma of the pancreas.

Gastrointest Cancer Res 2013 May;6(3):75-9

Division of Hematology and Oncology Department of Medicine.

Background: Adenosquamous carcinoma of the pancreas (ASCAP) is a rare histologic type of pancreatic carcinoma that constitutes 1% to 4% of all pancreatic exocrine malignancies. It has a clinical presentation similar to that of adenocarcinoma of the pancreas (ACP), but may have a worse overall prognosis, with most patients surviving for less than 2 years.

Methods: This was an institutional, retrospective, cohort analysis of 237 patients who underwent resection of pancreatic cancer with curative intent. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3737509PMC
May 2013
13 Reads